Research programme: diabetes therapy - Bayer

Drug Profile

Research programme: diabetes therapy - Bayer

Alternative Names: PACAP R3 SA

Latest Information Update: 09 Oct 2006

Price : $50

At a glance

  • Originator Bayer
  • Class
  • Mechanism of Action Vasoactive intestinal peptide type II receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 09 Oct 2006 No development reported - Preclinical for Diabetes mellitus in Germany (unspecified route)
  • 14 Feb 2001 Preclinical development for Diabetes mellitus in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top